An observational study in Coexistence of Cerebral and Coronary Atherosclerosis and Acute Ischemic Cerebrovascular Disease, sponsored by Xuanwu Hospital, Beijing. Recruiting at 1 site in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2022-01-11.
Sponsored by Xuanwu Hospital, Beijing · Observational
Coexistence of Cerebral and Coronary Atherosclerosis in Acute Ischemic Cerebrovascular Disease Patients Registry (CoCCA) is a single-center observational registry of patients hospitalized for acute ischemic cerebrovascular disease (AICVD) with atherosclerotic changes in both cerebral and coronary arteries.
This registry aims to establish quantified risk stratification and prognostic models, as well as suggest effective diagnostic and therapeutic strategies.
Atherosclerosis has exerted huge global burden as the common pathological process underlying ischemic heart disease and cerebrovascular disease. A substantial portion of acute ischemic cerebrovascular disease (AICVD) patients have both cerebral and coronary atherosclerosis, which is an omen of poor outcomes. But there is large evidence gap in these high-risk patients' prognosis-related factors, limiting the improvement of care quality.
Coexistence of Cerebral and Coronary Atherosclerosis in Acute Ischemic Cerebrovascular Disease Patients Registry (CoCCA) is a single-center prospective observational registry of patients hospitalized for AICVD with atherosclerotic changes in both cerebral and coronary arteries.
This registry aims to establish quantified risk stratification and prognostic models, as well as suggest effective diagnostic and therapeutic strategies.
The clinical, imaging and laboratory information will be collected at the baseline. During an estimated 5-year follow-up, the vessel-related diagnostic or monitoring procedures, treatment, functional status and new vascular events will be recorded by web-based patients' self-reports, investigators' regular telephone visits.
374 studies on the registry are indexed under Cerebrovascular Disorders; 129 are open to participants now.
This study's planned enrollment of 500 is above the median of 443 across 135 observational studies indexed under Cerebrovascular Disorders.
Browse Cerebrovascular Disorders studies →Xuanwu Hospital, Beijing is the lead sponsor of 346 studies on the registry; 217 are open to participants now.
Counted across the registry records on this site, refreshed daily.
acute ischemic cerebrovascular disease patients with coexistence of cerebral and coronary atherosclerosis
Exclusion Criteria:
acute ischemic cerebrovascular disease patients with coexistence of cerebral and coronary atherosclerosis.
Other: observational only- no intervention
observational only- no intervention
Rate of Major Adverse Cardiovascular Events
cardiovascular mortality (any mortality due to ischemic stroke, myocardial infarction, other cardiac diseases, or unobserved sudden death), ischemic stroke, myocardial infarction and unstable angina
Time frame: 1 year
Rate of Major Adverse Cardiovascular Events
cardiovascular mortality (any mortality due to ischemic stroke, myocardial infarction, other cardiac diseases, or unobserved sudden death), ischemic stroke, myocardial infarction and unstable angina
Time frame: 90 days
Functional Outcome
Percentage of patients with modified Rankin Scale (mRS) scores (minimum 0 and maximum 5) 3 to 5, who are considered to be disabled.
Time frame: 90 days
Rate of Ischemic Stroke
fatal and nonfatal ischemic stroke.
Time frame: 1 year
Rate of Acute Coronary Syndrome
fatal and nonfatal myocardial infarction and unstable angina
Time frame: 1 year
Rate of Cardiovascular Mortality
any mortality due to ischemic stroke, myocardial infarction, other cardiac diseases, or unobserved sudden death
Time frame: 1 year
Time to First Major Adverse Cardiovascular Event
from the date of enrollment until the date of first documented cardiovascular mortality (any mortality due to ischemic stroke, myocardial infarction, other cardiac diseases, or unobserved sudden death), ischemic stroke, myocardial infarction or unstable angina, whichever comes first, assessed up to 5 years
Time frame: 5 years
Time to First Ischemic Stroke
from the date of enrollment until the date of first documented ischemic stroke, assessed up to 5 years
Time frame: 5 years
Rate of Major Adverse Cardiovascular Events
cardiovascular mortality (any mortality due to ischemic stroke, myocardial infarction, other cardiac diseases, or unobserved sudden death), ischemic stroke, myocardial infarction and unstable angina
Time frame: 5 years
Rate of Ischemic Stroke
fatal and nonfatal ischemic stroke
Time frame: 5 years
Rate of Acute Coronary Syndrome
fatal and nonfatal myocardial infarction and unstable angina
Time frame: 5 years
Rate of Cardiovascular Mortality
any mortality due to ischemic stroke, myocardial infarction, other cardiac diseases, or unobserved sudden death
Time frame: 5 years
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Xuanwu Hospital, Beijing